Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWEBusiness Wire • 04/09/26
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead's First Option Target ExerciseBusiness Wire • 04/09/26
Gilead Sciences (GILD) Advances But Underperforms Market: Key FactsZacks Investment Research • 04/08/26
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 04/08/26
Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion TranscriptSeeking Alpha • 04/08/26
EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billionPRNewsWire • 04/07/26
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology PipelineBusiness Wire • 04/07/26
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth KnowingZacks Investment Research • 03/31/26
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?Zacks Investment Research • 03/27/26
Gilead Strengthens Inflammation Portfolio With Ouro Medicines DealZacks Investment Research • 03/24/26
Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolioProactive Investors • 03/24/26
Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset' Is Key to Future Gains.Barrons • 03/24/26
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune DiseasesBusiness Wire • 03/23/26